Sub-Macular Haemorrhage Clinical Research Grant

Call for applications: €2M available to address the best treatment option for Sub-Macular Haemorrhage caused by Age-related Macular Degeneration

Age-related macular degeneration (AMD) is the commonest cause of severe visual impairment in older adults in the developed world. Fight for Sight has identified AMD as one of our four Strategic Programmes focused on finding ways of stopping sight loss. 

Sub-macular haemorrhage (SMH) is caused by damage to the blood vessels and is a severe complication in some cases of exudative AMD. Several treatments have been developed that move the haemorrhage away from the macula, allowing surgeons to have access for treatment. These include displacement therapy, as well as gas and injection combination therapy, but the procedure carries significant risk of complications as well as a high health care cost.

Recent publications have shown that anti-VEGF monotherapy could be compatible with the resolution of SMH and improve visual function. However, to date, no statistically powered randomised control trial has shown which available treatment option is superior. 

Fight for Sight is collaborating with the European Society of Retina Specialists (EURETINA) to support a clinical trial in the field of the medical management of SMH. Applications are invited from suitably qualified senior principal investigators with a demonstrable track record in conducting and managing large multi-centre ophthalmology trials. 

Award

The Sub-Macular Haemorrhage Clinical Research Grant provides funding of up to €2,000,000 for a duration of between three and four years to comprehensively address the optimal treatment approach for SMH. The grant is open to applicants based in research institutions in the European Union and Horizon 2020 associated countries. Full details of criteria and conditions are contained in the Guidelines for Applicants

Grants are made on a fully competitive and peer reviewed basis. Fight for Sight is a member of the Association of Medical Research Charities (AMRC) and complies with its guidelines for best practice. EURETINA and Fight for Sight reserve the right to not award any grant funding if none of the submitted applications are deemed to be of sufficient quality. 

Eligibility

  • Applicants must have a tenured post at a recognised university, hospital or research institute within the European Union or Switzerland, Iceland, Norway, Israel, Turkey, Moldova, Faroe Islands, Ukraine, Tunisia, Georgia, Albania, Bosnia & Herzegovina, the former Yugoslav Republic of Macedonia, Montenegro, Serbia and Armenia.
  • Applicants, including their key research team members, must have a contract of full-time employment which extends beyond the termination date of the grant.
  • Applicants should be able to demonstrate prior experience and expertise in having previously conducted a clinically-led or industry randomised controlled trial or large multi-centre study, and have access to a clinical trials unit within their institution with demonstrable experience in running similar studies.
  • The proposal should demonstrate the clinical importance of the research to the European and global population, and be broadly translational with the objective of providing a comprehensive evidence base from which a clinical guideline may be produced in due course.
  • The grant is a purely clinical research funding initiative for the conduct of clinical research in human participants meeting relevant inclusion and exclusion criteria. No animal work should proposed as part of the project.
Under no conditions shall EURETINA or Fight for Sight hold any of the responsibilities or obligations of a trial “sponsor”. Any submission made to this Research Call shall include a written confirmation from the applicant’s host institute that the applicant, and the duly authorised officer of the host institute, fully understand and acknowledge all of the legal obligations and responsibilities of a trial “sponsor”, as per relevant legislation and guidelines, and that the applicant holds full authority from their institute to make an application to this Research Call to potentially act as a clinical trial “sponsor”.

Financial support and duration

  • Grant of up to €2,000,000 for a duration between three and four years
  • Additional criteria are set out in the Guidelines for Applicants.

Deadlines

The deadline for applications is 5pm GMT (6pm Central European Time) on Wednesday 31 October 2018.
Applications must be submitted via Fight for Sight’s online system grants.fightforsight.org.uk
Late applications will not be considered.

Contact Us

For any queries relating to your proposal please contact EURETINA and Fight for Sight here
For any queries regarding the use of the online system, please email Fight for Sight at Grants@fightforsight.org.uk.

Guidelines for Applicants
Terms and Conditions